Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Resources
  • Knowledge Base
  • Investigator led studies

Investigator Led Studies to Support Your Research

We are committed to advancing patient care through strategic support for qualified investigators who share our research priorities. Our assistance typically includes providing essential Revvity kits and associated reagents, research funding and in select cases, we may offer capital equipment on loan to facilitate meaningful investigations aligned with our business areas of interest.

All physicians, healthcare providers, researchers and institutions around the world who conduct their own research and share the same commitment are invited to submit a study proposal under the areas of interest including but not exclusive of:

Tuberculosis (TB)

  • Studies to optimize further use of the T-SPOT™.TB test as a means of diagnosis; for example (but not limited to), as a means of detecting disease progression, or for differentiating active versus latent TB infection, or for identifying other potential non-tuberculous mycobacteria infections.

Cytomegalovirus (CMV)

  • Interventional studies
  • Congenital CMV
  • Transplant

Other studies

  • Studies to explore performance of T-SPOT technology-based tests in immunosuppressed groups

All proposals are reviewed by a select review committee against criteria which includes scientific merit and alignment with the Company’s areas of interest. The investigator and/or institution responsibilities include study design, execution and compliance with all local and international regulatory requirements. Support is subject to availability of resource and conditioned upon an approved study concept proposal, full study protocol and full execution of a research support agreement by both parties.

For more information, please click here to download the Investigator Led Study Proposal form. Please submit both the cover letter and study protocol to us at researchstudies_idx@revvity.com.

Eligibility criteria

The proposed study should have scientific merit in a research area which complements the company's research.

The Investigator applying for an Investigator Led Study must meet the following criteria:

  • Have the appropriate infrastructure and resource in place to conduct the proposed study, e.g., the site has the scientific, technical, statistical and operational capabilities to conduct a study as a sponsor (including trained staff to execute the study)
  • Have already obtained IRB/Ethics approval, or be willing to obtain approval within 1 month of submission to Revvity
  • Have recent clinical research experience within the previous 3 years, evidenced by publications, congress presentations etc.
  • Have obtained Good Clinical Practice (GCP) training within the previous 3 years
  • Deliver to agreed timelines
  • Be able to meet all regulatory requirements, including writing of a final study report and manuscripts
  • Be able to publish the study in a peer-reviewed scientific journal

Products may not be licensed in accordance with the laws in all countries. Please check with your local representative for availability.

ON THIS PAGE
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.